Shaily Engineering Plastics Ltd (SHAILY) Q3FY25 Concall Summary - Dec-2024 Qtr
Performance Overview
- Shaily Engineering Plastics reported robust top-line growth of 25% reaching INR 197.6 crores in Q3 FY25, driven by a substantial 62% YoY increase in the Healthcare segment.
- Both gross margin and EBITDA margin improved to 47.5% and 23.4%, respectively.
- The company secured six new contracts for pen injectors and auto-injectors in the Healthcare segment.
- Two new global retail chains were added as customers in the Consumer segment, with supplies expected to commence in Q1 and Q2 of FY26.
- Despite geopolitical challenges, the Consumer segment grew by 20% YoY, while the Industrial segment experienced an 8% decline.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.